Best Compounded Tirzepatide Providers Under $200 per Month — 2026

Last reviewed: September 5, 2026 Last updated: September 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Five providers currently advertise compounded injectable tirzepatide at or below $200 per month, but each qualifies that headline in a different way. BrightMeds and AltRx publish the lowest effective rates—$119/month and $125/month respectively—but AltRx's promotion ends today (September 5, 2026) and neither figure is checkout-verified. Mochi Health delivers $129 all-in at the starting dose but uses per-dose pricing that rises as titration advances. OrderlyMeds meets the $200 threshold for the first two months only, then jumps to $299. Fridays Health advertises from $190/month on multi-month prepay, but the month-to-month rate and checkout figures remain unverified. Every sub-$200 figure in this roundup carries at least one of the following limitations: promotional expiration, dose restriction, prepayment requirement, or absence of checkout verification. Readers who prioritize transparent all-dose pricing and verified checkout figures may find greater decision utility in programs that publish standard ongoing rates, even when those rates exceed $200.

At-a-glance comparison: providers advertising tirzepatide under $200/month

Table captures advertised figures and terms as of September 4–5, 2026. All figures labeled "effective" or "from" indicate prepaid or conditional pricing.

How sub-$200 pricing works: prepayment, dose limits, and promotional windows

The five providers in this roundup reach the sub-$200 threshold through different mechanisms, and understanding those mechanisms is essential to interpreting what each figure actually delivers.

BrightMeds publishes a 3-month prepaid plan at $357 total, which works out to $119 per month—the lowest effective rate in this comparison. The plan covers any dose, and a public plan grid displays the figure without requiring intake. Four such cycles over twelve months total $1,428. The provider also offers a $149 monthly option, which places it within the sub-$200 range on a month-to-month basis. Neither figure has been checkout-verified, and we have no evidence regarding service quality, shipping reliability, or clinical support responsiveness.

AltRx advertises tirzepatide at $125 per month on a 12-month prepaid commitment, with shorter tiers at $130 (6-month), $144 (3-month), and $149 (1-month). All four tiers fall below $200. The promotional grid was captured September 4, 2026, and the promotion is stated to end September 5, 2026—today. We have not submitted payment or advanced past the advertised grid, and we have no post-promotion pricing or service-quality evidence. Readers considering AltRx should verify that the promotion remains active and confirm checkout figures before committing.

Mochi Health structures pricing by dose rather than by program tier. At the starting tirzepatide dose, medication costs $90 per month, and membership adds $39 per month (the first month of membership is $39, so there is no introductory discount on the membership itself, and ongoing months are also $39). The all-in cost at starting dose is $129 per month, and over twelve months that totals $1,548. However, as patients titrate to higher doses—an expected part of tirzepatide therapy—the medication component rises, and the total monthly cost will exceed $200. Mochi Health holds a 4.5-star rating on Trustpilot across approximately 18,000 reviews (captured September 4, 2026), though one captured individual report describes a provider appearing late to an appointment and not engaging during the visit. The $129 figure is accurate only for patients who remain at the starting dose; it is not a sustainable long-term rate for most users.

OrderlyMeds advertises a two-month starter period at $299 total—effectively $149.50 per month—followed by $299 per month ongoing. Only the first two months fall below $200. Months three through twelve cost $299 each, bringing the twelve-month total to $3,289, or an effective $274.08 per month. OrderlyMeds holds a 3.6-star rating on Trustpilot across approximately 634 reviews (captured September 4, 2026). Captured one-star and two-star individual reports cite fast charging but slow refunds, non-response to support inquiries, delayed shipping, unannounced pharmacy changes, and unwanted calls or texts after users requested opt-out. The starter pricing is genuine, but the ongoing rate and the service-quality reports should both inform the decision.

Fridays Health advertises tirzepatide from $190 per month effective on multi-month prepaid plans. The month-to-month rate has not been verified, and the checkout process has not been completed. Fridays Health's website contains promotional landing-page prices that differ from product-page standard prices, and we treat the product page as the more current source. The provider holds a 4.2-star rating on Trustpilot across approximately 4,700 reviews (captured September 4, 2026). The $190 figure is the company's own published headline; we cannot confirm what a user will pay at checkout, whether all doses are included, or what the month-to-month alternative costs.

Like-for-like twelve-month cost comparison

The table below expresses each provider's twelve-month cost under the terms that produce the advertised sub-$200 rate. Where a provider offers both prepaid and month-to-month options, both are shown. All prepaid per-month figures are labeled as such and represent our calculation.

Twelve-month totals and effective monthly rates are our calculations based on advertised terms captured September 4–5, 2026. Figures labeled "prepaid" require upfront payment. Mochi Health's $129 rate applies only at the starting dose. OrderlyMeds' blended rate reflects the two-month starter period followed by ten months at $299. Fridays Health's figure is an estimate derived from the advertised "from $190/month" claim; checkout verification is pending.

Decision factors: verification status, dose policy, and service quality

Price is one input; verification status, dose inclusivity, and service reliability are others. Every sub-$200 figure in this roundup carries at least one of the following limitations.

Verification status

BrightMeds, AltRx, and Fridays Health advertise their sub-$200 figures on public pages, but none has been checkout-verified. We have not submitted payment, received medication, or observed the service experience. Mochi Health's $129 rate is supported by current pricing documentation, but the per-dose model means the rate rises with titration. OrderlyMeds' starter pricing is advertised and is presumed accurate, but the twelve-month cost depends on the $299 ongoing rate, which we have not tested.

Dose policy

BrightMeds and AltRx advertise all-dose inclusion. Mochi Health's $129 rate applies only to the starting dose; higher doses cost more and will exceed $200 per month. OrderlyMeds' $299 standard rate after the starter period is not dose-segmented in the advertised terms, but confirmation at checkout is advisable. Fridays Health's dose policy under the $190 prepaid plan has not been verified.

Service quality and review evidence

Mochi Health holds a 4.5-star rating on Trustpilot across approximately 18,000 reviews, a scale that provides signal about aggregate satisfaction. One captured individual report describes a provider arriving late and not engaging during the visit—an anecdote, not a pattern, but relevant to readers evaluating responsiveness. OrderlyMeds holds a 3.6-star rating across approximately 634 reviews, with captured one-star and two-star individual reports citing fast charging but slow refunds, non-response to support requests, delayed shipping, unannounced pharmacy switches, and continued contact after opt-out requests. Fridays Health holds a 4.2-star rating across approximately 4,700 reviews, though we have not captured individual review themes. BrightMeds and AltRx have Trustpilot profile links, but no ratings or review volumes were captured.

Prepayment and promotional expiration

BrightMeds' $119 rate requires a $357 prepayment covering three months. AltRx's lowest rate requires a twelve-month prepayment, and the promotion is stated to end today (September 5, 2026). Fridays Health's $190 figure is tied to multi-month prepayment, though the specific term length and total outlay have not been verified. Mochi Health and OrderlyMeds operate on monthly billing, but OrderlyMeds' sub-$200 window lasts only two months.

Choose BrightMeds or AltRx if…

You are willing to prepay for multiple months, you can verify the advertised rates at checkout before committing, and you prioritize the lowest possible per-month effective cost over service-quality evidence or checkout verification. BrightMeds delivers $119 per month effective on a three-month cycle, and AltRx delivers $125 per month effective on a twelve-month prepayment—both well below any other option. However, neither figure is checkout-verified, neither provider has captured Trustpilot ratings or review volumes, and AltRx's promotion expires today. If the promotion has ended or the checkout figures differ from the advertised grid, the decision changes materially. Confirm the rates, confirm the dose policy, and confirm the prepayment terms before committing funds.

Choose Mochi Health if…

You are starting tirzepatide therapy, you expect to remain at the starting dose for an extended period (an uncommon clinical path for most patients), and you value a large Trustpilot review base (approximately 18,000 reviews at 4.5 stars, captured September 4, 2026) as a signal of aggregate service reliability. Mochi Health's $129 all-in rate is the lowest month-to-month figure that does not require prepayment, but it applies only to the starting dose. As you titrate upward—a standard part of GLP-1 therapy—the medication component will rise, and your total monthly cost will exceed $200. One captured individual report describes a provider arriving late and not engaging during the visit; readers who prioritize real-time clinical responsiveness should weigh that anecdote against the large positive review volume. Mochi Health is a genuine sub-$200 option for the starting-dose window, but it is not a sustainable sub-$200 option for long-term therapy.

Choose OrderlyMeds if…

You want a two-month trial at an effective $149.50 per month before committing to a higher ongoing rate, and you are comfortable with a 3.6-star Trustpilot rating (approximately 634 reviews, captured September 4, 2026) and captured individual reports citing fast charging but slow refunds, non-response to support inquiries, delayed shipping, unannounced pharmacy changes, and continued contact after opt-out. The $299 starter package (covering two months) is the lowest absolute outlay in this comparison, but the $299 per month ongoing rate brings the twelve-month total to $3,289—an effective $274.08 per month, well above the sub-$200 threshold. OrderlyMeds meets the $200 criterion for the starter period only; it is not a sub-$200 program over a twelve-month horizon. Readers who value service responsiveness, predictable refills, and clean opt-out processes may find the captured review themes decision-blocking, even if the starter price is attractive.

Choose Fridays Health if…

You are willing to prepay for multiple months, you can verify the advertised $190-per-month figure at checkout before committing, and you accept that the month-to-month rate and the specific prepayment term length remain unverified. Fridays Health holds a 4.2-star Trustpilot rating across approximately 4,700 reviews (captured September 4, 2026), a mid-scale signal of aggregate satisfaction, but the website contains promotional landing-page prices that differ from product-page standard prices. We treat the product page as the more current source, but even that page does not disclose the month-to-month rate or the full terms of the prepaid plan that produces the $190 figure. Confirm the checkout figures, confirm the dose policy, confirm the prepayment obligation, and confirm the refund or cancellation terms before committing funds.

Where PlexusDx fits

PlexusDx does not advertise tirzepatide below $200 per month. Compounded tirzepatide injection costs $289 per month on a month-to-month basis, $269 per month on a three-month plan (our calculation, prepaid), and $249 per month on a six-month plan (our calculation, prepaid). Every dose—from starting through maintenance—costs the same. Medication, clinician access, and shipping are included; there is no separate membership fee, no hidden dose tiers, no introductory rate that expires after the first cycle. Over twelve months, the month-to-month plan totals $3,468; the six-month plan (two cycles) totals $2,988, or $249 per month effective (our calculation, prepaid).

PlexusDx holds a 4.2-star rating on Trustpilot, with 76 percent of reviews at five stars and 81 percent at four stars or higher (captured September 4, 2026). The rating is verified, the pricing is checkout-verified, and the dose policy is transparent: same price at every dose, no surprises when you titrate. Readers who prioritize predictable monthly costs, all-dose inclusion, and verified service quality over the absolute lowest advertised rate may find PlexusDx's structure more decision-useful than programs that reach sub-$200 figures through promotional windows, dose restrictions, or unverified prepayment terms. Readers who prioritize the lowest possible per-month cost and are willing to navigate prepayment, promotional expiration, and verification uncertainty may find better economic fit with BrightMeds, AltRx, or Mochi Health during the starting-dose window.

Methodology and evidence freshness

This comparison draws on competitor website captures, checkout grids, and Trustpilot profiles captured September 4–5, 2026. PlexusDx pricing was captured September 5, 2026. BrightMeds' $119 and $149 figures come from a public plan grid captured September 4, 2026; no checkout verification was completed. AltRx's $125, $130, $144, and $149 figures come from a promotional grid captured September 4, 2026; the promotion is stated to end September 5, 2026, and no payment was submitted. Mochi Health's $90 medication and $39 membership figures come from current pricing documentation captured September 4, 2026. OrderlyMeds' $299 starter and $299 ongoing figures come from advertised terms captured September 4, 2026. Fridays Health's "from $190/month" claim comes from the provider's product page captured September 4, 2026; the month-to-month rate and checkout figures remain unverified. Trustpilot ratings and review volumes for Mochi Health, OrderlyMeds, and Fridays Health were captured September 4, 2026; individual review themes were captured the same day and are presented as anecdotes or individual reports, not as verified patterns. Twelve-month totals and effective monthly rates are our calculations based on the advertised terms; all prepaid per-month figures are labeled as such.

Frequently Asked Questions

Why do some providers advertise tirzepatide below $200 per month while others do not?

Providers that advertise tirzepatide below $200 per month typically use one or more of the following mechanisms: prepayment discounts that lower the effective monthly rate, per-dose pricing that applies only to starting doses, introductory periods that expire after one or two months, or promotional pricing with expiration dates. Standard month-to-month programs that include all doses without prepayment or promotional windows generally cost more than $200 per month.

Is compounded tirzepatide the same as branded Zepbound?

No. Compounded medications are not FDA-approved. The FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies. Branded Zepbound is FDA-approved; compounded tirzepatide is not the same as or interchangeable with the branded product.

If a provider advertises tirzepatide at $119 or $125 per month, why is that figure not checkout-verified?

Checkout verification requires submitting payment information, advancing through the full purchase flow, and confirming the final charge. BrightMeds' $119 figure and AltRx's $125 figure were captured from public pricing grids and promotional pages, but we did not complete checkout or submit payment. Advertised figures can differ from checkout figures due to state restrictions, eligibility criteria, add-on fees, or promotional terms that are clarified only at the final step. Readers should verify the rate at checkout before committing funds.

Does Mochi Health's $129 per month rate apply at every tirzepatide dose?

No. Mochi Health uses per-dose pricing. The $129 all-in rate (comprising $90 medication and first-month $39 membership, then $39 per month ongoing) applies only to the starting dose. As patients titrate to higher doses—a standard part of GLP-1 therapy—the medication component increases, and the total monthly cost exceeds $200. The $129 figure is accurate for the starting-dose window but is not sustainable for long-term therapy at higher doses.

What should I do if I see conflicting prices on a provider's website?

Treat the product page or checkout page as the most current source, note the capture date, and confirm the figure at checkout before committing payment. Some providers display promotional landing-page prices that differ from standard product-page prices, and introductory rates may apply only to the first month or first cycle. If the conflict persists at checkout, contact the provider directly and request written confirmation of the recurring rate, dose policy, and any prepayment or subscription terms before you commit funds.

Sources

• PlexusDx tirzepatide injection pricing and terms, accessed September 5, 2026
• BrightMeds public pricing grid, accessed September 4, 2026
• AltRx promotional pricing grid and terms, accessed September 4, 2026
• Mochi Health pricing documentation and product pages, accessed September 4, 2026
• OrderlyMeds advertised starter and ongoing pricing, accessed September 4, 2026
• Fridays Health product page and advertised tirzepatide rate, accessed September 4, 2026
• Mochi Health Trustpilot profile (4.5 stars, ~18,000 reviews), accessed September 4, 2026
• OrderlyMeds Trustpilot profile (3.6 stars, ~634 reviews) and individual review captures, accessed September 4, 2026
• Fridays Health Trustpilot profile (4.2 stars, ~4,700 reviews), accessed September 4, 2026
• PlexusDx Trustpilot profile (4.2 stars, 76% five-star, 81% four-star or higher), accessed September 4, 2026

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.